Tixagevimab/AZD8895 represents a unique medicinal approach utilizing paired monoclonal immunoglobulins. Specifically, these agents function by precisely connecting to the spike domain of the SARS-CoV-2 pathogen, https://www.targetmol.com/compound/tixagevimab